Gilles Hugues Tapolsky is a translational researcher with experience in multiple aspects of drug development, enabling him to ascertain the promises and challenges of novel drug development. He invented and developed the MCA® and BEMA® drug delivery technologies from the bench top to large-scale manufacturing, resulting in two products subsequently commercialized (Viractin™ and Onsolis™). He then focused his area of interest on cancer, contributing to the development of MTC-Dox, and he oversaw the R&D and clinical development of TPI287, a novel anticancer agent. Dr. Tapolsky then successfully led the translational efforts on glucose and lipid metabolism projects, resulting in the clinical development of PFK-158 (glycolysis inhibitor) in cancer and expanded his area of interest to neurodegenerative diseases, inflammation and antivirals. After joining Bexion, Dr. Tapolsky demonstrated BXQ-350’s mechanism of action and its impact on dysregulated sphingolipid metabolism, identified biomarkers and its potential clinical utility in neurodegenerative diseases.